Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04212117 · ClinicalTrials.gov registry record · NA
CALS Patient Activated Learning System (PALS)
A NA study of Communication and Health Knowledge, Attitudes, Practice, sponsored by Cornell University.
- Completed
- Registry status
- NA
- Development phase
- 232
- Enrollment target
- 1
- Study location
NCT04212117: Completed NA study of Communication and Health Knowledge, Attitudes, Practice, sponsored by Cornell University.
NCT04212117 is a NA study of Communication and Health Knowledge, Attitudes, Practice that has completed, run by Cornell University. The registered enrollment target is 232 participants, below the 1,414-participant average among 34 other Communication trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04212117, a NA study of Communication and Health Knowledge, Attitudes, Practice, has completed, sponsored by Cornell University.
- COMPLETED
- Registry status
- NA
- Development phase
- 232 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal in this line of inquiry is to test whether the Patient Activated Learning System (PALS) is effective in reducing disparities in access to reliable, easily understood health information, and whether this increased understanding has downstream consequences such as increases in trust in the medical system and self-management behaviors.
Primary Outcome
as measured by assessment questions on the nutrition information provided
Conditions Studied
Interventions
- OTHER WebMD
- OTHER The Patient Activated Learning System (PALS)
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2023-11-01 |
| Phase | NA |
What the finished NCT04212117 record still lists
NCT04212117 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 1,414-participant average among 34 other Communication trials with a reported enrollment target (84% lower).
The record links to 3 conditions, with Communication appearing as the primary indexed condition, and to 2 interventions - of which WebMD is the first listed.
NCT04212117 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04212117 about?
NCT04212117 is a clinical study titled "CALS Patient Activated Learning System (PALS)". The overall goal in this line of inquiry is to test whether the Patient Activated Learning System (PALS) is effective in reducing disparities in access to reliable, easily understood health information, and whether this increased understanding has downstream consequences such as increases in trust i...
What is the current status of trial NCT04212117?
This trial is currently completed. It is a NA study. The enrollment target is 232 participants. The study started on 2020-02-18. Estimated completion is 2023-11-01.
What conditions does trial NCT04212117 study?
This clinical trial studies the following conditions: Communication, Health Knowledge, Attitudes, Practice, Trust.
What interventions are being tested in trial NCT04212117?
The interventions under investigation include: WebMD (OTHER), The Patient Activated Learning System (PALS) (OTHER).
Who is sponsoring clinical trial NCT04212117?
This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04212117 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Communication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04212117's enrollment target sits among peer trials
232 22nd of 34 higher than 13 of 34 other Communication trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Communication trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Seminar in Unwavering Empowering Presence Optimized for Rehabilitation Teams
RECRUITING · NA
-
Communication Strategies to Increase HPV Vaccination Intention
RECRUITING · NA
-
Multicenter HomeVENT: Home Values and Experiences Navigation Track
RECRUITING · NA
-
Alcohol and Sexual Communication Among Couples in the Laboratory
RECRUITING · NA
-
Families of Youth with Developmental Disabilities: a Theory-Based Intervention
RECRUITING · NA
-
Timing of Physician Rounds for Antepartum Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI